Drug Profile
Research programme: glaucoma gene therapy - Mayo Clinic/Oxford BioMedica
Alternative Names: Glaucoma-GTLatest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Mayo Clinic
- Developer Mayo Clinic; Oxford BioMedica
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Glaucoma